← Research library

Anxiolytic use of the known Bromantane molecule — RU2175229C2

Patent disclosure · 2001

What the patent describes
Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
Reported evidence
Identifies Ladasten as the known Bromantane molecule and cites earlier psychostimulant certificate 860446 and immunostimulant patent 1826906.

Reported patent results

Findings described in words

The patent reports less fear-related behavior with greater exploration, alongside behavioral activation.

Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.

Population or model Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.

Results · Description: strain-specific behavioral comparisons, Tables 5–6 narrative.
MeasureResultComparison, timing and statistics
Maze/exploration resultReduced fear-like response in the high-fear strain and increased activity in the more exploratory strainNo transcribed group means or human anxiety outcome
Diazepam comparisonThe disclosure describes a different activation/sedation profileThis is a laboratory behavioral distinction, not a clinical noninferiority or safety finding

Strain-specific animal behavior does not establish broad human anxiety efficacy or absence of stimulant adverse effects. Human clinical records remain separate.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. Ladasten anxiolytic-use disclosure; the patent provides a development source rather than independent clinical replication.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2175229C2 ↗ · 2001-10-27
Earliest priority / filing
1999-12-22 / 1999-12-22
Original applicant / assignee
Научно-исследовательский институт фармакологии РАМН
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20228716 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Anxiolytic agent

Inventors: С.Б. Середенин; М.А. Яркова; Б.А. Бадыштов; тин Б.М. П; Б.М. Пятин; Н.И. Авдюнина; И.С. Морозов; Т.А. Воронина; Г.Г. Незнамов.

RU2175229C2

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • A new-use patent is not evidence of clinical effectiveness or regulatory status.
  • The earlier certificates are cited here; the original documents that would establish priority have yet to be located.

Source details

Original patent text checked, including identity and references to the earlier certificates.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

S. B. Seredenin, M. A. Yarkova, B. A. Badyshtov, B. M. Pyatin, N. I. Avdyunina, I. S. Morozov, T. A. Voronina, G. G. Neznamov. Anxiolytic use of the known Bromantane molecule — RU2175229C2 Russian patent RU2175229C2

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards